Agenda

Agenda:

Day One: Tuesday 2 October 2007

07.30

Registration

08.30

BALLROOM
Keynote Welcome Address:
Dr Peter Reinisch, Partner, Global Life Science Ventures

09.00

Keynote Address:
Heinrich Christen, Partner, Ernst & Young
The Importance of Nanotechnology in Life Sciences: The Results of an Ernst & Young Study

09.20

Keynote Address:
Dennis Purcell, Senior Managing Director, Aisling Capital

09.45

Finance & Investment Panel

Chair:	Stephanie Léouzon, Managing Director, European Healthcare, Credit Suisse
Panellists:	Dr Klaus Breiner, Partner, BB Biotech Ventures Dr Rudolph Gygax, Managing Director, Novartis Venture Fund Dr Richard Parkes, Senior Research Analyst, Piper Jaffray Dr Yvonne Gunsch-Wegmann, Vice President, Head of Issuer & Investor Relations, SWX Swiss Exchange Dr David Reese, Managing Director, Yorkville Advisors

10.45

Coffee Break

11.15 - 13.00

Small-Cap Listed Company Presentations

ROOM ZURICH
Chair: TBA

ROOM BASEL
Chair: Dr Douglas Pretsell
Northbank Communications

ROOM BERN
Chair: Dr Peter Kalinka
Tiburon Bio Consulting

11.15

BB Biotech
Dr Christian K. Lach
Partner

Archimedes Pharma
Richard de Souza
CEO

Phynova Group
Tony Mills
Director, Business Development

11.30

Clinuvel Pharmaceuticals
Philippe Wolgen
CEO

Curis
Daniel R. Passeri
CEO & President
Michael P. Gray
CFO & COO

CardioVascular BioTherapeutics
Prof Dr Thomas J. Stegmann
Co-Founder & Co-President & CMO

11.45

Addex Pharmaceuticals
Chris Maggos
Head of IR & Communications

Intercell
Gerd Zettlmeissl
CEO

Oridion Systems
Walter Tabachnik
CFO

12.00

Algeta
Thomas Ramdahl
CEO

Micromet
Dr Christian Itin
CEO & President

Photocure
Kjetil Hestdal
CEO & President

12.15

GENEART
Christian Ehl
CEO & CFO
Prof Dr Ralf Wagner
CEO & CSO

LipoNova
Dr Oliver Keilhack
CFO

Silence Therapeutics
Jeffery S. Vick
CEO

12.30

Intercytex
Nick Higgins
CEO

Wilex
Peter Llewellyn-Davis
CFO & Member of the Executive Board

biolitec
Dr Wolfgang Neuberger
CEO

12.45

Questions to Panelists

Questions to Panelists

Questions to Panelists

13.00

Lunch

14.00 - 17.30

Company Presentations: Listed and Private Companies

ROOM ZURICH
Chair: Laurent Feniou
ABN AMRO Rothschild

ROOM BASEL
Chair: Yvonne Alexander
Citigate Dewe Rogerson

ROOM BERN
Chair: Dr Peter Kalinka
Tiburon Bio Consulting

14.20

Santhera Pharmaceuticals
Barbara Heller
CFO

MHB
Dr Bahige Baroudy
CSO & President

14.35

BioXell
Dr Francesco Sinigaglia
CEO

Biota Holdings
Dr Leigh Farrell
Vice President

Pacific Edge Biotechnology
David Darling
CEO

14.50

CeNeS Pharmaceuticals
Neil R. Clark
CEO

Newron Pharmaceuticals
Luca Benatti
CEO & Managing Director

MolMed
Prof Claudio Bordignon
CEO & President

15.05

LifeCycle Pharma
Nicolas Nemery
SVP Commercial Operations

OctoPlus
Hans Pauli
CFO

Epiphany Biosciences
Fred Volinsky
CEO & Founder

15.20

Sinclair Pharma
Dr Michael Flynn
CEO

PolyMedix
Nick Landekic
CEO & President

United Technologies
“Russian Technologies”
Prof Ivan Vasilenko, CEO
Dr Igor Zaytsev, Consultant
Dr Ali Turgiev, VP Int. Operations

15.35

SkyePharma
Dr Ken Cunningham
COO

Faust Pharmaceuticals
Thomas Seoh
CEO

United Technologies
continued

15.50

Questions to Panelists

Questions to Panelists

Questions to Panelists

16.00

ROOM ZURICH
Chair: Dr Juerg Eckhardt
BB Biotech Ventures

ROOM BASEL
Chair: Dr Stephan McCormack
Global Life Science Ventures

16.00

Alltracel Pharmaceuticals
Tony Richardson
CEO

Lipoxen
M. Scott Maguire
CEO

16.15

Biotie Therapies
Dr Timo Veromaa
CEO & President

Green Hills Biotechnology
Michael Tscheppe, CFO
Dr Thomas Muster, CEO & CSO

16.30

Cosmo Pharmaceuticals
Chris Tanner
CFO & Head of IR

TiGenix
Frank Hazevoets
CFO

16.45

Cellerix
Eduardo Bravo
CEO

Cellzome
Timothy P.W. Edwards
CEO & President

17.00

Bayhill Therapeutics
Mark Schwartz
CEO

Oxford Genome Sciences
Dr Christian Rohlff
CEO

17.15

Questions to Panelists

Questions to Panelists

17.30

Devices Panel

Chair:	Jürg Zürcher, Partner, Ernst & Young
Panellists:	Dr Christian K. Lach, Partner, Bellevue Asset Management AG Dr Olivier Litzka, Partner – Life Sciences, Edmond de Rothschild Investment Partners Dr Jörg Neermann, Partner, LSP Christopher Meyer, Head of Business Development and Strategic Planning, Medtronic

18.15

Cocktail Reception

Day Two: Wednesday 3 October 2007

07.30

Registration

08.30

Global Trends Investor Panel

Chair:	Seth Yakatan, Partner, Katan Associates
Panellists:	Dr Klaus Stoeckemann, Partner – Healthcare Ventures, 3i Dr Karl Naegler, Principal, Atlas Ventures Antoine Papiernik, Managing Partner, Sofinnova Partners Dr Simon Turton, Managing Director, Warburg Pincus

09.15

Pharma Partnering Panel

Chair:

Dimitri Dimitriou, Chief Executive Officer, DyoDelta Biosciences

Panellists:

Dr Andrew Wood, Executive Director, Research Acquisitions, Europe, Lilly
Dr Margaret Beer, Director, Scientific Liaison, Licensing and External Research, Europe, Merck & Co., Inc.
Dr Markus Ewert, Global Head of Search & Evaluation Cardiovascular & Metabolism, Novartis Pharmaceuticals
Dr Alex Chanas, Director, Licensing and Development, Pfizer
Dr Janet Greeson, Chief Executive Officer, Samaritan Pharmaceuticals

10.00

The Changing Interface between Big Pharma and VC

Chair:	Dr Genghis Lloyd-Harris, Partner, Abingworth
Panellists:	Dr Véronique Bouchet, Head of Venture Strategy, AstraZeneca Steve Krognes, Head M&A, Member Roche Finance Executive Committee, F.Hoffmann-La Roche Deborah Harland, General Partner, SR One Dr Axel Polack, General Partner, TVM Capital GmbH

10.45

Coffee Break

11.15-13.00

Sector Workshops: Private Companies Presentations

ROOM ZURICH
THERAPEUTICS WORKSHOP
Chair: Dr Axel Polack
TVM Capital GmbH

ROOM BASEL
IMMUNOLOGY/ONCOLOGY WORKSHOP
Chair: Dr Klaus Breiner
BB Biotech Ventures

ROOM BERN
MIXED WORKSHOP
Chair: Dr Markus Hosang
BioMedInvestor AG

11.15

ACE BioSciences
Ingelise Saunders
CEO

Cylene Pharmaceuticals
Dr William Rice
CEO

Quanta Fluid Solutions
Martin Johnson
CEO

11.30

Affectis Pharmaceuticals
Jesper Wiklund
CBO

Chroma Therapeutics
Ian Nicholson
CEO

Rowiak
Dr Holger Lubatschowski
CEO

11.45

REVOTAR
Dr Martin Pôhlchen
CEO

ESBATech
Dr Dominik Escher
CEO

CellTraffix
Thomas Fitzgerald
CEO

12.00

Kuros Biosurgery
Alistair Irvine
Director of Business Development

GlycoVaxyn
Dr Urs Tuor
Head of Corp. Development

Syntaxin
Patrick Doyle
CEO

12.15

Direvo Biotech
Andreas F. Richter
CFO

Optimata
Guy Malchi
CEO

Synosia Therapeutics
Dr Ian Massey
CEO & President

12.30

Lectus Therapeutics
Dr Roland Kozlowski
CEO

Palau Pharma
Dr Ignacio Faus
CEO

TcLand
Alain Huriez
CEO & Chairman

12.45

Questions to Panelists

Questions to Panelists

Questions to Panelists

13.00

Lunch

14.00 - 15.40

Sector Workshops:Private Companies Presentations

ROOM ZURICH
Chair: Dr Karl Naegler
Atlas Ventures

ROOM BASEL
Chair: Dr Kuno Jung
Global Life Science Ventures

ROOM BERN
Chair: Dr Peter Kalinka
Tiburon Bio Consulting

14.00

AM-Pharma
Bart Wuurmann
CEO

AVONTEC
Dr Thomas Schulze
CEO

DBV Technologies
Jean-François Biry
CEO & Chairman

14.15

Apeiron Biologics
Hans Loibner
CEO

Evolva
Neil Goldsmith
CEO & Managing Director

Shogoo Pharmaceuticals
Cees Winnips
CSO

14.30

Borean Pharma
Johanna Holldack
CEO

f-star
Dr Eugen Stermetz
CFO

Karus Therapeutics
Dr Simon Kerry
CEO

14.45

NatImmune
Dr Martin Bonde
CEO

MerLion Pharmaceuticals
Dr Anthony Buss
CEO

Brane Discovery
Carlo Farina
CEO

15.00

Phenex Pharmaceuticals
Claus Kremoser
CEO

JADO Technologies
Mr Charl van Zyl
CEO

Archivel Farma
Dr Pere-Joan Cardona
CSO

15.15

XBiotech
Dr Thomas Kündig
Director Research

Nabriva Therapeutics
Dr Rodger Novak
COO & Managing Director

15.30

Questions to Panelists

Questions to Panelists

Questions to Panelists

15.40

Stem Cell’s from Investor Perspective Panel

Chair:	Steven Dickman, CEO, CBT Advisors
Panellists:	Mr Thomas Fitzgerald, CEO, CellTraffix Inc. Navid Malik, Pharmaceutical Analyst, Collins Stewart Plc Dr Aaron T. Chuang, Manager Cellular Neurobiology, GlaxoSmithKline Linda Powers, Managing Director, Toucan Capital

16.15

Close of Conference

* to be confrmed

Click here to download a pdf version of the Programme and Agenda.